SG Americas Securities LLC Sells 77,766 Shares of 10x Genomics, Inc. (NASDAQ:TXG)

SG Americas Securities LLC cut its holdings in 10x Genomics, Inc. (NASDAQ:TXG) by 76.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 23,578 shares of the company’s stock after selling 77,766 shares during the quarter. SG Americas Securities LLC’s holdings in 10x Genomics were worth $532,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Algert Global LLC increased its stake in 10x Genomics by 39.4% during the second quarter. Algert Global LLC now owns 117,964 shares of the company’s stock worth $2,294,000 after acquiring an additional 33,364 shares during the last quarter. Susquehanna Fundamental Investments LLC boosted its holdings in shares of 10x Genomics by 166.7% in the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 201,671 shares of the company’s stock worth $3,923,000 after purchasing an additional 126,052 shares during the period. Deerfield Management Company L.P. Series C bought a new position in shares of 10x Genomics during the 2nd quarter valued at approximately $11,612,000. AQR Capital Management LLC raised its holdings in 10x Genomics by 230.9% during the 2nd quarter. AQR Capital Management LLC now owns 315,180 shares of the company’s stock valued at $6,130,000 after buying an additional 219,945 shares during the period. Finally, Squarepoint Ops LLC lifted its position in 10x Genomics by 1.1% in the second quarter. Squarepoint Ops LLC now owns 515,883 shares of the company’s stock worth $10,034,000 after buying an additional 5,720 shares during the last quarter. Institutional investors own 84.68% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on TXG shares. Leerink Partnrs upgraded 10x Genomics to a “strong-buy” rating in a research report on Tuesday, September 3rd. Morgan Stanley dropped their price objective on 10x Genomics from $50.00 to $46.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Stephens reiterated an “overweight” rating and issued a $30.00 target price on shares of 10x Genomics in a research note on Thursday, October 10th. The Goldman Sachs Group lowered their target price on shares of 10x Genomics from $26.00 to $16.00 and set a “sell” rating for the company in a research note on Tuesday, July 9th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of 10x Genomics from a “buy” rating to a “hold” rating and reduced their price target for the stock from $55.00 to $25.00 in a research note on Wednesday, July 10th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, 10x Genomics has an average rating of “Moderate Buy” and an average price target of $30.60.

Insiders Place Their Bets

In related news, insider Benjamin J. Hindson sold 4,351 shares of the firm’s stock in a transaction on Thursday, August 22nd. The shares were sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares of the company’s stock, valued at $7,788,711.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other 10x Genomics news, CFO Justin J. Mcanear sold 2,961 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total value of $66,711.33. Following the sale, the chief financial officer now owns 143,242 shares in the company, valued at approximately $3,227,242.26. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,351 shares of the firm’s stock in a transaction that occurred on Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $98,028.03. Following the sale, the insider now directly owns 345,704 shares in the company, valued at $7,788,711.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,061 shares of company stock valued at $316,794. 10.03% of the stock is owned by insiders.

10x Genomics Stock Performance

Shares of TXG stock opened at $15.91 on Wednesday. 10x Genomics, Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $57.90. The firm has a market capitalization of $1.90 billion, a price-to-earnings ratio of -7.13 and a beta of 1.85. The stock’s 50-day simple moving average is $21.33 and its 200-day simple moving average is $22.98.

10x Genomics (NASDAQ:TXG) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.15. The business had revenue of $153.10 million during the quarter, compared to analysts’ expectations of $150.90 million. 10x Genomics had a negative net margin of 37.90% and a negative return on equity of 28.23%. As a group, equities analysts forecast that 10x Genomics, Inc. will post -1.32 earnings per share for the current year.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.